Sensei Bio reports Q4 2024 cash of $41.3M; Phase 1/2 solnerstotug data shows 14% ORR in PD-(L)1 resistant tumors

Sensei Biotherapeutics, Inc.

Preliminary Phase 1/2 dose expansion data: 14% ORR (3x historical PD-(L)1 rechallenge rates) and 62% DCR in PD-(L)1 resistant hot tumors; one complete response in Merkel cell carcinoma.
Target enrollment of 60 patients achieved in dose expansion cohort; full data expected by year-end 2025.
Net loss $30.2M for FY2024 (vs $34.1M FY2023); cash, equivalents and marketable securities $41.3M as of Dec 31, 2024, with runway into Q2 2026.
Solnerstotug well-tolerated: no dose-limiting toxicities; majority of adverse events Grade 1-2; 7% Grade 1 cytokine release syndrome.
Corporate updates: Q4 restructuring, appointment of Josiah Craver as Principal Financial Officer, and Dr. Ron Weitzman as part-time CMO.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.